
Akums Subsidiary Receives ₹52.7 Cr Demand Notice from NPPA
Akums Drugs and Pharmaceuticals Ltd's wholly-owned subsidiary, Pure and Cure Healthcare Private Limited, has received a Demand Notice from the National Pharmaceutical Pricing Authority (NPPA) for manufacturing the formulation 'Lanol 1000 mg injection'. The notice, dated October 13, 2026, and received on October 15, 2026, alleges that the fixed MRP exceeded prescribed limits under The Drugs (Prices Control) Order, 2013. The total demand amounts to ₹52,74,68,193 (₹52.74 Crore), comprising overcharging of ₹18,94,80,649 (₹18.94 Crore) for batches manufactured between December 2017 and August 2024, a penalty of ₹18,94,80,649 (₹18.94 Crore), and interest of ₹14,85,06,895 (₹14.85 Crore) up to October 30, 2026. The notice was also issued to Hetero Healthcare Limited (Marketer) and Abaris Healthcare Private Limited. Pure & Cure, as a manufacturer, states that the primary responsibility for responding lies with the marketer, Hetero Healthcare Limited, citing supply agreements that hold the marketing entity liable for DPCO violations.
Key Highlights
- Subsidiary received ₹52.7 Cr demand notice from NPPA.
- Notice alleges violation of Drug Price Control Order.
- Demand includes overcharging, penalty, and interest.
- Marketer Hetero Healthcare holds primary response responsibility.
Price Impact
More from AKUMS